×
About 1,830 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  634 results

Hypogammaglobulinemia in pediatric kidney transplant recipients.
https://doi.org/10.1007/s00467-022-05757-1
Pediatric Nephrology (Berlin, Germany); Dimitriades V, Butani L

Oct 1st, 2022 - Infections remain the most common cause of hospitalization after kidney transplantation, contributing to significant post-transplant morbidity and mortality. There is a growing body of literature that suggests that immunoglobulins may have a signi...

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
https://clinicaltrials.gov/ct2/show/NCT05357781

Sep 27th, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...

Lymphoma as an Exclusion Criteria for CVID Diagnosis Revisited.
https://doi.org/10.1007/s10875-022-01368-5
Journal of Clinical Immunology; Allain V, Grandin V et. al.

Sep 27th, 2022 - Hypogammaglobulinemia in a context of lymphoma is usually considered as secondary and prior lymphoma remains an exclusion criterion for a common variable immunodeficiency (CVID) diagnosis. We hypothesized that lymphoma could be the revealing sympt...

Break down the barriers of auto-inflammation: How to deal with a monogenic auto-inflamm...
https://doi.org/10.1111/imm.13579
Immunology Vergneault H, Picard C et. al.

Sep 25th, 2022 - In the past few years, the spectrum of monogenic systemic auto-inflammatory diseases (MSAID) has widely expanded beyond the typical recurrent fever. Immuno-haematological features, as cytopenias, hypogammaglobulinemia, hypereosinophilia, lymphopro...

Gastrointestinal involvement of common variable immunodeficiency: A diagnostic challeng...
https://doi.org/10.1177/14782715221088963
The Journal of the Royal College of Physicians of Edinburgh; Gangadharan H, Paul VJ et. al.

Sep 24th, 2022 - A 35-year-old male presented with fatigue for 1 month and was found to have megaloblastic anaemia. Further evaluation showed low globulin levels and pan hypogammaglobulinemia. Past history was significant for chronic small bowel diarrhoea and bila...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  41 results

Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
https://clinicaltrials.gov/ct2/show/NCT05357781

Sep 27th, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...

Genetic Studies of Chronic Active Epstein-Barr Disease
https://clinicaltrials.gov/ct2/show/NCT00032513

Sep 23rd, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Sep 21st, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
https://clinicaltrials.gov/ct2/show/NCT02579967

Sep 21st, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
https://clinicaltrials.gov/ct2/show/NCT03702920

Sep 14th, 2022 - Approximately 380 subjects with cirrhosis, ACLF, and high risk of hospital mortality (ACLF-1b, ACLF-2, or ACLF-3a) will be included in this study after obtaining written informed consent. In case of hepatic encephalopathy (HE), written informed co...

see more →

News  51 results

Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab
https://www.mdedge.com/dermatology/article/252371/autoimmune-diseases/interstitial-granulomatous-dermatitis-adverse
Katherine G. Beuerlein, BS, Elise D. Martin, MD et. al.

Mar 3rd, 2022 - The number of monoclonal antibodies developed for therapeutic use has rapidly expanded over the last decade due to their generally favorable adverse effect (AE) profiles and efficacy. 1 Tumor necrosis factor α inhibitors and general integrin antago.

Second CAR T-Cell Therapy Approved for Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/97437

Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...

Zanubrutinib sBLA for Waldenström Macroglobulinemia Accepted in China
https://www.onclive.com/view/zanubrutinib-sbla-for-waldenstr-m-macroglobulinemia-accepted-in-china

Jan 21st, 2022 - The China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) as a treatment for adult patients with Waldenström macroglobulinemia.1 The application is supported by...

FDA Approval Sought for Teclistamab for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-approval-sought-for-teclistamab-for-relapsed-refractory-multiple-myeloma

Dec 29th, 2021 - A biologics license application seeking the approval of the off-the-shelf, T-cell redirecting bispecific antibody, teclistamab (JNJ-64007957), for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.1 The ap...

Kahl Weighs the Complexities of Treatment Selection in Indolent Lymphoma
https://www.onclive.com/view/kahl-weighs-the-complexities-of-treatment-selection-in-indolent-lymphoma

Oct 6th, 2021 - Brad S. Kahl, MD Optimizing treatment for patients with indolent non-Hodgkin lymphoma (iNHL) has become a challenge as the frontline and recurrent treatment settings continue to evolve, said Brad S. Kahl, MD. "The management of [recurrent] indol...

see more →